Literature DB >> 21309935

A comparison of the hospital costs of open vs. minimally invasive surgical management of necrotizing pancreatitis.

Edwin Beenen1, Lisa Brown, Saxon Connor.   

Abstract

BACKGROUND: Infected necrotizing pancreatitis is a major burden for both the patient and the health care system. Little is known about how hospital costs break down and how they may have shifted with the increasing use of minimally invasive techniques. The aim of this study was to analyse inpatient hospital costs associated with pancreatic necrosectomy.
METHODS: A prospective database was used to identify all patients who underwent an intervention for necrotizing pancreatitis. Costs of treatment were calculated using detailed information from the Decision Support Department. Costs for open and minimally invasive surgical modalities were compared.
RESULTS: Twelve open and 13 minimally invasive necrosectomies were performed in a cohort of 577 patients presenting over a 50-month period. One patient in each group died in hospital. Overall median stay was 3.8 days in the intensive care unit (ICU) and 44 days on the ward. The median overall treatment cost was US$ 56,674. The median largest contributors to this total were ward (26.3%), surgical personnel (22.3%) and ICU (17.0%) costs. These did not differ statistically between the two treatment modalities.
CONCLUSIONS: Pancreatic necrosectomy uses considerable health care resources. Minimally invasive techniques have not been shown to reduce costs. Any intervention that can reduce the length of hospital and, in particular, ICU stay by reducing the incidence of organ failure or by preventing secondary infection is likely to be cost-effective.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2011        PMID: 21309935      PMCID: PMC3048969          DOI: 10.1111/j.1477-2574.2010.00267.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  32 in total

1.  The APACHE II score is unreliable to diagnose necrotizing pancreatitis on admission to hospital.

Authors:  Paul Georg Lankisch; Bettina Warnecke; Dirk Bruns; Hans-Martin Werner; Franziska Grossmann; Karl Struckmann; Gisbert Brinkmann; Patrick Maisonneuve; Albert B Lowenfels
Journal:  Pancreas       Date:  2002-04       Impact factor: 3.327

2.  Determining the economic cost of ICU treatment: a prospective "micro-costing" study.

Authors:  Anne Marie McLaughlin; Judy Hardt; James B Canavan; Maria B Donnelly
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

3.  Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach.

Authors:  Michael G T Raraty; Christopher M Halloran; Susanna Dodd; Paula Ghaneh; Saxon Connor; Jonathan Evans; Robert Sutton; John P Neoptolemos
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

4.  IAP Guidelines for the Surgical Management of Acute Pancreatitis.

Authors:  Waldemar Uhl; Andrew Warshaw; Clement Imrie; Claudio Bassi; Colin J McKay; Paul G Lankisch; Ross Carter; Eugene Di Magno; Peter A Banks; David C Whitcomb; Christos Dervenis; Charles D Ulrich; Kat Satake; Paula Ghaneh; Werner Hartwig; Jens Werner; Gerry McEntee; John P Neoptolemos; Markus W Büchler
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

5.  A step-up approach or open necrosectomy for necrotizing pancreatitis.

Authors:  Hjalmar C van Santvoort; Marc G Besselink; Olaf J Bakker; H Sijbrand Hofker; Marja A Boermeester; Cornelis H Dejong; Harry van Goor; Alexander F Schaapherder; Casper H van Eijck; Thomas L Bollen; Bert van Ramshorst; Vincent B Nieuwenhuijs; Robin Timmer; Johan S Laméris; Philip M Kruyt; Eric R Manusama; Erwin van der Harst; George P van der Schelling; Tom Karsten; Eric J Hesselink; Cornelis J van Laarhoven; Camiel Rosman; Koop Bosscha; Ralph J de Wit; Alexander P Houdijk; Maarten S van Leeuwen; Erik Buskens; Hein G Gooszen
Journal:  N Engl J Med       Date:  2010-04-22       Impact factor: 91.245

6.  Pancreatic necrosectomy: North American mortality is much lower than expected.

Authors:  Purvi Y Parikh; Henry A Pitt; Molly Kilbane; Thomas J Howard; Attila Nakeeb; C Max Schmidt; Keith D Lillemoe; Nicholas J Zyromski
Journal:  J Am Coll Surg       Date:  2009-10-17       Impact factor: 6.113

Review 7.  Prediction of mortality in acute pancreatitis: a systematic review of the published evidence.

Authors:  G Gravante; G Garcea; S L Ong; M S Metcalfe; D P Berry; D M Lloyd; A R Dennison
Journal:  Pancreatology       Date:  2009-08-04       Impact factor: 3.996

8.  Timing and impact of infections in acute pancreatitis.

Authors:  M G Besselink; H C van Santvoort; M A Boermeester; V B Nieuwenhuijs; H van Goor; C H C Dejong; A F Schaapherder; H G Gooszen
Journal:  Br J Surg       Date:  2009-03       Impact factor: 6.939

9.  Closing the audit loop is necessary to achieve compliance with evidence-based guidelines in the management of acute pancreatitis.

Authors:  Saxon J Connor; Andrew R Lienert; Lisa A Brown; Philip F Bagshaw
Journal:  N Z Med J       Date:  2008-06-06

10.  A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units.

Authors:  Onnen Moerer; Enno Plock; Uchenna Mgbor; Alexandra Schmid; Heinz Schneider; Manfred Bernd Wischnewsky; Hilmar Burchardi
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  3 in total

1.  Effects of prophylactic antibiotics in acute pancreatitis.

Authors:  Povilas Ignatavicius; Astra Vitkauskiene; Juozas Pundzius; Zilvinas Dambrauskas; Giedrius Barauskas
Journal:  HPB (Oxford)       Date:  2012-04-01       Impact factor: 3.647

2.  Infected pancreatic necrosis: drain first, but do it better.

Authors:  John A Windsor
Journal:  HPB (Oxford)       Date:  2011-05-05       Impact factor: 3.647

3.  Minimally invasive procedures in severe acute pancreatitis treatment - assessment of benefits and possibilities of use.

Authors:  Jacek Szeliga; Marek Jackowski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-04-01       Impact factor: 1.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.